ReviewFrontiers in oncology2026
Beyond traditional staging system: Tumor-Node-Metastasis-Blood staging system improves treatment decisions and prognostic stratification in cancer patients.
Review in Frontiers in oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Artificial intelligence in non-small cell lung cancer: transforming diagnosis, treatment, and prognostic evaluation.Frontiers in medicine · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: The traditional Tumor-Node-Metastasis (TNM) staging system for solid tumors relies on anatomical assessment but possesses inherent limitations in capturing systemic micrometastases and molecular-level disease burden. Recently, the Tumor-Node-Metastasis-Blood (TNMB) staging system has garnered significant attention. It aims to provide a systematic synthesis of the origin of the TNMB staging system, its current applications in tumors, and its future prospects, while evaluating its potential value in enhancing early diagnosis, prognostic assessment, and the precision of therapeutic decision-making. Methods: A systematic literature search was conducted in PubMed and Web of Science databases from 2018 to 2026 using keywords related to neoplasms and TNMB staging system. Articles were screened for inclusion, and 21 studies focusing on cutaneous T-cell lymphoma and lung cancer were included for analysis. Results: The TNMB staging system enhances risk stratification and prognostic accuracy in both cutaneous T-cell lymphoma and non-small cell lung cancer. In cutaneous lymphoma, TNMB staging system correlates with disease progression, treatment response, and molecular biomarkers. In lung cancer, integrating circulating tumor DNA (ctDNA) into TNMB staging system improves recurrence prediction and guides adjuvant therapy decisions, outperforming traditional TNM staging in prognostic discrimination. Beyond CTCL and non-small cell lung cancer (NSCLC), the utility of key biomarkers such as ctDNA for refining staging precision suggests a broader potential for the TNMB framework, even in cancers where its formal application is still forthcoming. Conclusion: The TNMB staging system represents a transformative approach in oncology by incorporating blood-based molecular data into traditional anatomical staging. It enables earlier detection of micrometastases, improves risk stratification, and supports personalized treatment strategies. Despite challenges in standardization and clinical integration, TNMB staging system holds significant promise for advancing precision oncology across multiple cancer types.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.